Literature DB >> 30429030

Real-life treatment practice for malignant pleural mesothelioma in Belgium.

Michael Rosskamp1, Gilles Macq2, Kristiaan Nackaerts3, Marleen Praet4, Liesbet Van Eycken5, Jan P Van Meerbeeck6, Harlinde De Schutter7.   

Abstract

OBJECTIVES: Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer, for which treatment is often limited to palliative combination chemotherapy. Multimodality-therapy, including radical surgery, is largely restricted to clinical trials, leaving its benefit currently unclear. This study aimed to get a comprehensive view on real-world MPM treatment at the Belgian population level, to assess survival and to identify prognostic factors.
MATERIALS AND METHODS: The study period covered the incidence years 2004-2012 (N = 1453). Starting from the Belgian Cancer Registry, additional information regarding patient characteristics, diagnosis and treatment was retrieved from multiple data sources. Adjusted cox proportional-hazard regression models using time-dependent covariates were performed to assess survival in relation to treatment patterns and centre volume.
RESULTS: Sixty-nine percent of patients underwent tumour-directed treatment, mostly cisplatin-pemetrexed chemotherapy. Radical surgery was mainly performed in younger patients with epithelioid subtype. Centre volume, surgery and chemotherapy showed a positive relation with survival in univariable analyses, but only chemotherapy remained significantly relevant in multivariable analyses. Younger patients, females, and epithelioid subtypes also independently had a better survival.
CONCLUSION: This large population-based study provides insights in MPM treatment practice in Belgium. Centre volume and surgery being related to survival in univariable analyses, only chemotherapy remained prognostic after adjustment.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Malignant pleural mesothelioma; Population-based research; Real-life treatment practice; Survival and prognostic factors

Mesh:

Substances:

Year:  2018        PMID: 30429030     DOI: 10.1016/j.lungcan.2018.10.009

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  2 in total

1.  Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.

Authors:  Wanyuan Cui; Sanjay Popat
Journal:  Drugs       Date:  2021-06-09       Impact factor: 9.546

2.  A Trimodality, Four-Step Treatment including Chemotherapy, Pleurectomy/Decortication and Radiotherapy in Early-Stage Malignant Pleural Mesothelioma: A Single-Institution Retrospective Case Series Study.

Authors:  Giovanni Vicidomini; Carminia Maria Della Corte; Antonio Noro; Raimondo Di Liello; Salvatore Cappabianca; Alfonso Fiorelli; Valerio Nardone; Gaetana Messina; Giuseppe Viscardi; Angelo Sangiovanni; Riccardo Monti; Marina Accardo; Floriana Morgillo; Fortunato Ciardiello; Renato Franco; Mario Santini
Journal:  Cancers (Basel)       Date:  2021-12-29       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.